News and Press Releases
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
22 September 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 22, 2025
electronRx to Launch pDx App for Remote Chronic Respiratory Disease Management
Technology detects digital biomarkers to help monitor lung function and optimise therapeutic outcomes for patients electronRx to showcase pDx at HLTH 2025 (19–22 Oct, Las Vegas). 18 September 2025 --...
Category: Other, Pharmaceutical
Posted: September 18, 2025
Teknomek launches new laboratory furniture range
17 September 2025 - Teknomek, the UK’s leading manufacturer and supplier of hygienic furniture and equipment, has launched a brand-new furniture range for laboratories. Manufactured from mild steel, with white...
Category: Manufacturing and Packing
Posted: September 17, 2025
Terumo Blood and Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America
Regulatory approvals in 14 countries expand treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis Approvals align with the historic World Health Assembly resolution on rare diseases. 16...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: September 16, 2025
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degeneration Neovascular or “wet” age-related macular degeneration can...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 11, 2025
Evonik and Ethris enter strategic partnership to expand offerings for nucleic acid delivery
Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic Accelerating RNA-based therapeutic solutions for customers through...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2025
Terumo BCT and PwC Belgium Join Forces to Break Barriers in Access to Advanced Cell and Gene Therapies
2 September 2025 -- Brussels, Belgium -- Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, and PwC Belgium today announce a new collaboration focused on driving equitable...
Category: Biotechnology, Drug Discovery, Logistics, Manufacturing and Packing
Posted: September 8, 2025
PlasmidFactory founder Dr. Martin Schleef honored with the NRW Innovation Award 2025
8 September 2025 -- Düsseldorf/Bielefeld, Germany -- The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored today in Düsseldorf with the Innovation Award 2025 of the...
Category: BioManufacturing, Other, Pharmaceutical
Posted: September 8, 2025
CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals as the global event returns to Germany
Frankfurt, Germany - Friday, Sept 25th - Informa Markets will once again welcome the global pharmaceutical industry to CPHI Frankfurt 2025, running from October 28 to 30 at Messe Frankfurt. The...
Category:
Posted: September 5, 2025
Johnson & Johnson Launches First Daily Disposable Toric Contact Lens Designed to Deliver on the Specific Needs of Low and High Astigmatic Patients in United Kingdom and Ireland (UKI)
World’s #1 Selling Contact Lens Brand ACUVUE Brings Pioneering Innovation For Astigmatic Patients, Providing Visual Clarity And Comfort The First Toric Lens to have an Optimised Design according to Cylinder...
Category: Drug Delivery, Other, Pharmaceutical
Posted: September 4, 2025
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
4 September 2025 -- Paris, France -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will...
Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 4, 2025
Bavarian Nordic launches VIMKUNYA in the UK for the Prevention of Chikungunya, for individuals aged 12 years and older
3 September 2025 -- London, UK -- Bavarian Nordic A/S announced today the official UK launch of the VIMKUNYA® chikungunya vaccine (recombinant, absorbed). This follows the recent approval by the...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025
Bavarian Nordic GmbH Fraunhoferstrasse 13 D-82152 Martinsried
Fidia Farmaceutici enters the UK market with the acquisition of Altacor Ltd
Marking another significant milestone in its ongoing international expansion, the Company enters the rapidly-growing UK ophthalmology market, a key therapeutic area for the Group 3 September 2025 -- Abano Terme,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU
